| Ticker Details |
Actinium Pharmaceuticals, Inc
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's product portfolio includes Iomab-B and Actimab-A.
|
| IPO Date: |
January 1, 2003 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$34.51M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.16 | 4.03%
|
| Avg Daily Range (30 D): |
$0.03 | 3.81%
|
| Avg Daily Range (90 D): |
$0.04 | 3.99%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.06M |
| Avg Daily Volume (30 D): |
.11M |
| Avg Daily Volume (90 D): |
.15M |
| Trade Size |
| Avg Trade Size (Sh.): |
476 |
| Avg Trade Size (Sh.) (30 D): |
433 |
| Avg Trade Size (Sh.) (90 D): |
297 |
| Institutional Trades |
| Total Institutional Trades: |
47 |
| Avg Institutional Trade: |
$1.86M |
| Avg Institutional Trade (30 D): |
$2.2M |
| Avg Institutional Trade (90 D): |
$2.2M |
| Avg Institutional Trade Volume: |
.24M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.11M |
| Avg Closing Trade (30 D): |
$3.87M |
| Avg Closing Trade (90 D): |
$3.87M |
| Avg Closing Volume: |
431.92K |
|
|
| Financials |
| |
TTM |
Q2 2026 |
Q1 2026 |
|
Basic EPS
|
$.36
|
$.89
|
$-.18
|
|
Diluted EPS
|
$.36
|
$.89
|
$-.18
|
|
Revenue
|
$35.09M
|
$35M
|
$M
|
|
Gross Profit
|
|
|
|
|
Net Income / Loss
|
$11.31M
|
$27.9M
|
$-5.52M
|
|
Operating Income / Loss
|
$9.56M
|
$27.57M
|
$-5.9M
|
|
Cost of Revenue
|
|
|
|
|
Net Cash Flow
|
$-24.9M
|
$5.86M
|
$-5.86M
|
|
PE Ratio
|
|
|
|
|
|
|
